{"id":"furosemide-dose-escalation","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Hypokalemia"},{"rate":"5-10","effect":"Hyperuricemia"},{"rate":"1-5","effect":"Ototoxicity (at high doses)"},{"rate":"5-15","effect":"Dehydration"},{"rate":"5-10","effect":"Hypotension"},{"rate":"5-10","effect":"Hyperglycemia"},{"rate":"1-5","effect":"Hyponatremia"}]},"_chembl":{"chemblId":"CHEMBL35","moleculeType":"Small molecule","molecularWeight":"330.75"},"_fixedAt":"2026-03-30T15:53:56.129464","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Furosemide blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing reabsorption of sodium, potassium, and chloride. This results in increased osmotic pressure in the tubular lumen, reducing water reabsorption and producing a potent diuretic effect. Dose escalation refers to titrating the dose upward to achieve desired diuretic response in patients with fluid overload or edema.","oneSentence":"Furosemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting increased urine output and fluid elimination.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:46.629Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Edema associated with congestive heart failure"},{"name":"Edema associated with hepatic cirrhosis"},{"name":"Edema associated with renal disease"},{"name":"Hypertension"}]},"_fixedFields":["pubmed(11)"],"trialDetails":[{"nctId":"NCT02356159","phase":"PHASE1, PHASE2","title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-24","conditions":"Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT05287100","phase":"NA","title":"To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation.","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2022-01-01","conditions":"Cirrhosis, Liver","enrollment":35},{"nctId":"NCT02575963","phase":"PHASE1, PHASE2","title":"Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients","status":"COMPLETED","sponsor":"Actinium Pharmaceuticals","startDate":"2012-10","conditions":"AML","enrollment":40},{"nctId":"NCT04622709","phase":"PHASE2","title":"Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2020-10-07","conditions":"Chronic Kidney Disease Requiring Chronic Dialysis","enrollment":39},{"nctId":"NCT04907123","phase":"PHASE3","title":"Systematic Escalation of diuREtics With Natriuresis in Heart Failure Patients: SERENA Trial","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2021-10","conditions":"Heart Failure","enrollment":198},{"nctId":"NCT04679571","phase":"NA","title":"Efficacy of Targeted And Response-Guided Albumin Therapy Versus Standard Medical Treatment In Outcomes Of Recurrent Ascites In Patients With Decompensated Cirrhosis.","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2020-12-30","conditions":"Decompensated Cirrhosis","enrollment":100},{"nctId":"NCT00904488","phase":"PHASE4","title":"Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2008-10","conditions":"Acute Decompensated Heart Failure","enrollment":11},{"nctId":"NCT01384253","phase":"PHASE1","title":"Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy","status":"COMPLETED","sponsor":"Orano Med LLC","startDate":"2011-07","conditions":"Breast Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"recentPublications":[{"date":"2025 Oct 24","pmid":"41300560","title":"Furosemide-Induced Nephrocalcinosis in Premature Neonates: A Critical Review of Observational Data.","journal":"Children (Basel, Switzerland)"},{"date":"2025 Dec","pmid":"41114681","title":"AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review.","journal":"Gastroenterology"},{"date":"2025 May","pmid":"39674969","title":"Door-to-Diuretic Time and Outcomes in Acute Heart Failure: A Scoping Review.","journal":"American journal of cardiovascular drugs : drugs, devices, and other interventions"},{"date":"2023 Jul 1","pmid":"37223933","title":"Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial.","journal":"JAMA cardiology"},{"date":"2023 Jan","pmid":"36181769","title":"Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial.","journal":"European journal of heart failure"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lasix"],"phase":"marketed","status":"active","brandName":"Furosemide dose escalation","genericName":"Furosemide dose escalation","companyName":"University of North Carolina, Chapel Hill","companyId":"university-of-north-carolina-chapel-hill","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Furosemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting increased urine output and fluid elimination. Used for Edema associated with congestive heart failure, Edema associated with hepatic cirrhosis, Edema associated with renal disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}